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Abstract
Introduction: Pulmonary Hypertension (PH) is a disorder of the pulmonary vasculature with high mortality and bears a  large 
economic burden on the healthcare system. We conducted a review of the largest inpatient database in the United States and 
analyzed the trends in hospitalizations due to PH from the turn of the century (2000) to 2013 to evaluate the rate of hospitalizations 
and determine the cost and mortality associated with PH.
Material and methods: We analyzed the National Inpatient Sample Database (NIS) for all patients in which PH (Primary or Se-
condary) or cor pulmonale was the primary discharge diagnosis (ICD-9: 416.0, 416.8 and 416.9) from 2000 to 2013. The NIS is 
the largest all-payer inpatient database in the United States and contains data from approximately 8 million hospital stays each 
year. The statistical significance of the difference in the number of hospital discharges, lengths of stays and associated hospital 
costs over the study period was calculated.
Results: In 2000, there were 12,066 hospital admissions with the principal discharge diagnosis of pulmonary hypertension, which 
increased to 13,605 admissions in 2013 (p < 0.001). The mean length of stay for PH increased from 5.89 days to 6.67 days during 
this period (p = 0.04). During the same period, the hospital charges increase by 174.5% from US$ 24,973 in 2000 to US$ 68,545 
in 2013 (Adjusted for inflation). The aggregate cost of hospital visits of a patient increased by 209.5% from US$ 301,324,218 in 
2000 to US$ 932,554,725 in 2013.
Conclusion: The number of inpatient discharges related to PH has increased even though the number of inpatient discharges 
with PAH has been reported to be lower in literature. The mean length of stay has also shown a mild increase. This increase 
is associated with a significant increase in the mean and aggregate cost. These inpatient costs associated with PH contribute 
significantly to the total healthcare burden. Further research on cost-effective evaluation and management of PH is required. 
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Introduction
Pulmonary hypertension (PH) is a chronic 
and devastating disease characterized by pro-
gressive increases in pulmonary arterial pressure 
and pulmonary vascular resistance eventually le-
ading to right ventricular failure and death [1, 2]. 
It is characterized by a mean pulmonary arterial 
pressure (mPAP) ≥ 25 mm Hg at rest and pul-
monary arterial hypertension (PAH), a specific 
subgroup of PH, has the added criteria of a pulmo-
nary capillary wedge pressure (PCWP) ≤ 15 mm 
Hg [3–5]. The World Health Organization (WHO) 
currently classifies PH into 5 groups (Table 1) [6]. 
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The exact prevalence of PH in the world is 
unknown, and its real burden may be largely 
underestimated [7]. A  surveillance from the 
United States Centers for Disease Control and 
Prevention from 1980 to 2002, demonstrated 
an increased rates of hospitalization associated 
with PH with around 200,000 hospitalizations 
having PH as a primary or secondary diagnosis 
[8]. The severe symptoms of PH often present at 
an advanced stage of the disease process leading 
to a delay in diagnosis [9]. Hospitalizations re-
lated to PH also create a  significant economic 
burden due to the costly nature of diagnostic 
procedures and medications. Most of the epi-
demiological information about PH is obtained 
from specialized disease registries [10, 11]. 
With the recently expanding research into the 
etiology, diagnosis and management of PH, it 
is important to provide updated epidemiolo-
gical data regarding the disease to aid in the 
understanding of health utilization costs. Thus 
we conducted a review of the largest inpatient 
database in the United States and analyzed the 
trends in hospitalizations due to PH from the 
turn of the century (2000) to 2013. 
Material and methods
The National Inpatient Sample (NIS) databa-
se was used to obtain a population-based estimate 
of national trends of PH. The NIS database is 
a tool developed as a part of the Healthcare Cost 
and Utilization Project (HCUP), and is sponso-
red by the Agency for Healthcare Research and 
Quality. The NIS database is the largest publicly 
available all-payer inpatient care database in the 
United States. The NIS database is designed to 
approximate a 20% sample of US community 
(nonfederal) hospitals, and is organized accor-
ding to geographic region, hospital ownership, 
location, teaching status, and number of beds 
amongst others. The 2000 NIS database contains 
a total of approximately 7.5 million records. The 
2013 NIS database contains a total of about 7.1 
million records drawn from 44 states and includes 
information from 4363 hospitals. This database 
is drawn from all over the United States and 
represents a majority of the US population. The 
immense size of the NIS database provides an 
exceptional representative sample of the general 
US population. In order to identify cases of PH, 
the NIS database was queried for hospital data on 
all discharges with ICD-9-CM primary diagnosis 
codes of 416.0, 416.8 and 416.9 (Primary pulmo-
nary hypertension, Secondary pulmonary hyper-
tension & cor-pulmonale) from 2000 to 2013. In 
2012, the NIS database was modified to draw data 
from all hospitals in the hospital frame to provide 
more efficient sampling while maintaining the 
same strata. The NIS database provides only ad-
ministrative data for analysis and patient-specific 
clinical data are not available. It was assumed that 
the patients were formally diagnosed with PH by 
means of right heart catheterization. 
Variables recorded
Recorded patient demographics include age 
and gender. Hospital characteristics included bed 
size (small, medium, and large) and owner (gover-
nment, private non-profit or private for-profit) and 
the region of location (Northeast, Midwest, South 
& West). Hospital bed size varies depending on the 
hospital’s location and teaching status. Small ho-
spitals range from 1 to 299 beds, medium hospi-
tals range from 50 to 499 beds, and large hospitals 
range from 100 to 500 or more beds. The payer 
status for all admissions was also considered and 
divided into categories of Medicare, Medicaid, 
private insurance, uninsured, and other. “Hospital 
Charges” are defined as the amount the hospital 
charged for the patient’ s entire hospital stay, but 
it does not include professional (physician) fees. 
As per NIS, “aggregate charges” or the national 
“bill” is defined as the sum of all charges for all 
hospital stays in the United States and “length of 
stay” as the number of nights the patient remained 
in the hospital per stay.
Statistics
The trends for average length of stay, mean 
total charges, mortality and total number of di-
scharges specifically for the diagnosis of PH were 
plotted and analyzed from 2000 to 2013. The 
frequency of discharges with PH was calculated 
by dividing the annual number of discharges with 
a primary discharge diagnosis of PH by the total 
number of all discharges listed in the NIS for each 
year. The Pearson Chi-Square test was used to 
Table 1.  World Health Organization classification  
of pulmonary hypertension (PH)
Group 1 Pulmonary arterial hypertension
Group 2 PH due to left heart disease
Group 3 PH due to lung disease and/or hypoxemia
Group 4 Chronic thromboembolic PH and other pulmonary 
artery obstructions
Group 5 PH due to unclear multifactorial mechanisms
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compare proportions between 2000 and 2013. 
All statistical calculations were computed using 
SAS (version 9.4, The SAS Institute, NC). HCUP 
provided consolidated data for all codes of PH 
(416.0,416.8 and 416.9). The aggregate charges 
(“ the national bill ”) were calculated by sum-
ming the individual ICD-9 codes (416.0,416.8 
and 416.9). Annual charges reported are the 
raw charges adjusted for the long-term avera-
ge health-care annual inflation rate (Bureau 
of Labor Statistics: http:// data.bls.gov/) such 
that all dollar values relate to 2013 dollars. 
The temporal trend in length of stay and ho-
spital charges with PH observed from 2000 to 
2013 was assessed via polynomial regression, 
in which the most appropriate functional form 
for the trend was assessed by examination of 
regression diagnostic plots. A linear shape plot 
was determined to be appropriate for discharge 
count, length of stay, and mortality. The stati-
stical significance of the trend was determined 
via Spearman’s correlation technique to obtain 
p-values. P-value < 0.05 was considered to be 
statistically significant. 
In addition to the percentages available ad-
jacent to the data in the tables, the frequency per 
10,000 admissions for each variable was calcu-
lated. Thus the numbers are a representation of 
the density of patients admitted/discharged with 
PH compared with the total number of hospital 
discharges per category. Each frequency was cal-
culated by dividing the number of patients with 
pulmonary hypertension by the total discharges 
in a  specific categorical variable for each year 
and multiplying the number by 10,000. Rates 
that have been compared over time using Poisson 
regression, which yields relative rates (RRs) that 
express the ratio of rate per 10,000 in 2013 to that 
in 2000. P-value of < 0.05 was considered to be 
statistically significant. 
Results
Results characterizing the trends in PH related 
hospitalizations, length of stay, cost, mortality and 
discharges have been outlined in Tables 2 and 3. 
Number and cost of PH discharges
From 2000 to 2013, the total number of ho-
spital discharges with the principal diagnosis of 
PH increased by 12.8% from 12,066 to 13,605 
(p < 0.001). Thus the frequency of hospital di-
scharges with PH as the principal diagnosis incre-
ased from 3.42 per 10,000 discharges to 3.82 per 
10,000 discharges (RR = 1.12, 95% CI: 1.09–1.15; 
p < 0.001). The linear trend of PH admissions and 
discharges also showed a statistically significant 
increase from 2000 to 2013 (R² = p) (Fig. 1).
The average length of stay of a PH admission 
showed an increase from 5.89 days in 2000 to 6.67 
days in 2013 (Fig. 2). The aggregate cost of hospi-
tal visits of a patient with the principal diagnosis 
of PH increased 209.5% from US$ 301,324,218 
in 2000 to US$ 932,554,725 in 2013. The mean 
hospital charges per patient increased 174.5% 
from US$ 24,973 in 2000 to US$ 68,545 in 2013 
(Adjusted for inflation). 
Patient characteristic by age
The highest number of patient discharges in 
both 2000 and 2013 was noted in the 65–84 age 
group. The frequency of discharges was noted to 
be higher in the 45–64 age group in 2000 (5.74 
per 10,000 discharges) while it was highest in the 
65–84 age group in 2013 (5.56 per 10,000 dischar-
ges). The increase in the frequency of discharge 
rates was most remarkable in age groups 65–84 
and > 85 years. A drop in the rate of discharges 
was noted in the age groups 18–44 (R = 0.85, 
95%CI: 0.80–0.90; p < 0.001) and 45–64 (RR = 
0.90, 95% CI: 0.86–0.94; p < 0.001). 
Patient characteristics by sex
The number of PH admissions and discharges 
was noted to be greatest in females both in 2000 
and 2013, increasing from 3.7 per 10,000 dischar-
ges in 2000 to 4.41 per 10,000 discharges in 2013. 
(RR = 1.19, 95% CI: 1.16–1.23; p < 0.001). The 
increase for males did not show a statistically 
significant rise and increased from 3 per 10,000 
discharges in 2000 to 3.03 per 10,000 discharges 
in 2013 (p = 0.74).
Patient characteristics by payer group
The relative frequency of PH discharges 
increased for all types of payer groups except 
Medicaid over this 13-year period. The highest 
absolute number of PH discharges was in the 
Medicare group in both 2000 and 2013, which 
increased from 4.93 per 10,000 discharges in 2000 
to 5.71 per 10,000 discharges in 2013 (RR = 1.16, 
95% CI: 1.12–1.20; p < 0.001). While in 2000, the 
frequency of discharges from the Medicare group 
was higher (2.87 per 10, 000 discharges), the drop 
of discharges from Medicare group meant that the 
frequency of discharge of patients with Private 
insurance was higher in 2013 (2.66 per 10,000 
discharges). There was a modest increase in the 
number of discharges in both the uninsured and 
other payer groups as noted in Table 1. 
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Table 2. Trends in characteristics of PH related hospitalizations from 2000 to 2013
Categori-
cal  
Variable
2000
PH
 (N, )
2013
PH
 (N, )
2000
Total
 (N, )
2013 
Total
 (N, )
PH per 
10,000  
admissions 
in 2000
PH per 
10,000  
admissions
in 2013
RR  (95% CI) P-value
All discharges 12,066 13,605 35,300,425 35,597,792 3.42 3.82 1.12  
(1.09–1.15)
< 0.001
Mean age  
(years)
Age group  
(years)
< 1 146 175 4,541,823 4,232,808 0.32 0.41 1.29 (1.03–1.60) 0.024
1–17 234 415 1,626,291 1,393,028 1.44 2.98 2.07 (1.76–2.43) < 0.001
18–44 2,216 1,710 9,617,360 8,727,809 2.3 1.96 0.85 (0.80–0.90) < 0.001
45–64 4,110 4,520 7,159,251 8,753,270 5.74 5.16 0.90 (0.86–0.94) < 0.001
65–84 4,637 5,330 9,855,601 9,581,434 4.7 5.56 1.18 (1.14–1.22) < 0.001
> 85 723 1,455 2,493,840 2,906,938 2.9 5.01 1.73 (1.58–1.89) < 0.001
Sex Male 4,318 4,585 14,372,338 15,154,195 3 3.03 1.01 (0.97–1.05) 0.74
Female 7,744 9,020 20,920,986 20,436,357 3.7 4.41 1.19 (1.16–1.23) < 0.001
Payer Medicare 6,294 7,990 12,763,012 13,986,550 4.93 5.71 1.16 (1.12–1.20) < 0.001
Medicaid 1,667 1,825 5,814,171 7,417,129 2.87 2.46 0.86 (0.80–0.92) < 0.001
Private  
Insurance
3,456 2,890 13,787,690 10,851,650 2.51 2.66 1.06 (1.01–1.12)  < 0.05
Uninsured 324 505 1,724,382 2,070,848 1.88 2.44 1.30 (1.13–1.50) < 0.001
Other 306 390 1,070,236 1,216,485 2.86 3.20 1.12 (0.97–1.30) 0.13
Median  
income for zip 
code
Low  
($0–35,999)
* 4,160 * 10,199,933 * 4.08
Not low  
($36,000+)
* 9,120 * 24,599,165 * 3.71
Owner Govern-
ment
1,837 2,020 4,608,704 4,291,755 3.99 4.71 1.18 (1.11–1.26) < 0.001
Private, 
not- 
-for-profit
9,050 9,920 26,471,999 26,111,822 3.42 3.80 1.11 (1.08–1.14) < 0.001
Private, 
for-profit
1,179 1,665 4,219,722 5,194,215 2.79 3.21 1.15 (1.06–1.24) < 0.001
Bed Size Small 1,148 1,495 4,049,244 4,884,892 2.84 3.06 1.08 (0.10–1.17) 0.05
Medium 2,955 3,205 9,621,509 9,512,936 3.07 .3.37 1.10 (1.04–1.15) < 0.001
Large 7,945 8,905 2,1578,915 21,199,964 3.68 4.2 1.14 (1.11–1.18) < 0.001
Region Northeast 2,096 2,405 7,009,155 6,730,965 2.99 3.57 1.19 (1.13–1.27) < 0.001
Midwest 3,072 3,275 8,221,274 8,004,912 3.74 4.09 1.09 (1.04–1.15) < 0.001
South 4,566 4,900 13,340,212 13,818,031 3.42 3.55 1.04 (0.10–1.08) 0.085
West 2,332 3,025 6,729,784 7,043,884 3.47 4.30 1.24 (1.17–1.31) < 0.001
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Table 3. Trends in characteristics of PH related hospitalizations & discharges from 2000 to 2013 
2000
PH
2013
PH
RR(CI) P-value
Total number of discharges 12,066 13605 – < 0.01
Length of Stay 5.89 days 6.67 days – 0.04
Charges (mean, adjusted for inflation) $24973 $68545 – –
Total charges (adjusted for inflation) $301,324,218 $932,554,725 – –
Mortality 807 (6.69%) 620 (4.56%) 0.70 (0.63–0.77) < 0.001
Routine Discharges 8232 (68.23%) 7835 (57.59%) 0.90 (0.88–0.92) < 0.001
Another short term hospital 396 (3.28%) 585 (4.30%) 1.30 (1.14–1.47) < 0.001
Nursing Home or Rehabilitation 1094 (9.07%) 1760 (12.94%) 1.38 (1.28–1.48) < 0.001
Home Health Care 1490 (12.35%) 2690 (19.77%) 1.50 (1.42–1.60) < 0.001
Against medical advice 46 (0.38%) 105 (0.77%) 2.02 (1.43–2.85) < 0.001
Figure 1. Trends in in-hospital discharges
Pulmonary Hypertension discharges by 
hospital ownership, characteristics and 
region
There was a rise in the number of PH dischar-
ges from all 3, hospital owner categories from 
2000 to 2013 (Government, Private (Not-for-pro-
fit) and Private (For-profit). The overall highest 
number of discharges were seen from Private, 
not-for-profit hospitals. The highest increase in 
frequency was seen in discharges from Govern-
ment hospitals (RR= 1.18, 95% CI: 1.11–1.26; p < 
0.001). In 2000 a patient with PH was more likely 
to be admitted and discharged from a hospital 
with a large number of beds (65.85%) as compa-
red to hospital with medium or small number of 
beds, and this trend continued in 2013 (69.45%). 
The South had the highest number of both 
PH discharges and total discharges in 2000 as well 
as 2013. Even then, the increase in the frequency 
of discharge in the South from 2000 to 2013 was 
not statistically significant (p = 0.085). On the 
contrary, the Midwest had the highest frequency 
of PH discharges in 2000 with 3.74 per 10,000 
discharges while in 2013 it was highest in the 
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Figure 2. Trends in length of stay
Figure 3. Trends in mortality
West with 4.3 per 10,000 discharges. The total 
number and frequency of discharges in all regions 
except the South showed a statistically significant 
increase (Table 1).
Pulmonary hypertension discharges with 
mortality rates and discharge disposition
The percent mortality of patients admitted 
and discharged with a principal diagnosis of PH 
decreased from 6.69% in 2000 to 4.56% in 2013 
with a statistically significant decrease in the li-
near trend (R² =; p < 0.01) (Fig. 3). The number 
of routine discharges decreased from 68.23% to 
57.59% of the total discharges. On the other hand, 
discharges from the hospital to nursing home and 
rehabilitation increased from 9.07% to 12.94% 
(RR = 1.38, 95 CI: 1.28–1.48; p < 0.001). Also 
notable was the fact patients discharged with 
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Figure 4. Trends graph in mortality of pulmonary hypertension and cost along with sentinel events in management of pulmonary arterial hypertension
home health care increased from 12.35% of total 
discharges in 2000 to 19.77% of total PH discharges 
in 2013 (RR= 1.50, 95% CI: 1.42–1.60; p < 0.001). 
Discussion
Pulmonary hypertension continues to be 
a challenging disease to diagnose and manage 
due to its heterogeneous etiology and complex 
pathogenesis. There appears to be a  growing 
number of diagnoses of PH, possibly due to the 
greater awareness of this once considered, rare 
disease or due to better screening and diagnostic 
availability i.e. right heart catheterizations and 
echocardiography. However determining the 
exact epidemiology has proven challenging due 
to a  lack of global consensus on prevalence. In 
the United Kingdom, a prevalence of 97 cases per 
million with a female: male ratio of 1.8 has been 
reported and in the United States the age-stan-
dardized death rate ranges between 4.5 and 12.3 
per 100,000 population [12]. The United States’ 
national inpatient database provides valuable 
information, exploring aspects of patient cha-
racteristics, epidemiology as well as providing 
a snapshot of economic burden of this disease. 
Discharges and length of stay
Our study demonstrated that in the national 
trend of the United States; there was a statisti-
cally significant increase in the overall number 
of hospitalizations for PH from 2000 through to 
2013. This was in spite of the fact that a recent 
study reported a decline in the number of hospi-
talizations associated with PAH (Group 1) alone 
from 2001 through 2012 [13]. This would indicate 
that the rise in the number of hospitalizations due 
to PH can actually be attributed to an increase 
in admissions due to secondary causes of PH 
i.e. WHO Group 2–5 PH. A review of literature 
did not yield any comparative data in terms of 
hospital admissions for all WHO groups of PH. 
Most available data in literature focuses of WHO 
Group I PAH, possibly due to the fact that there 
is available pharmacological treatment. 
This overall increase in hospitalizations may 
be attributed to a number of causes. One expla-
nation may be the increased awareness about 
PH in the modern management era. While PH 
was once known as an orphan disease [8], new 
effective therapies to treat PAH are now available. 
Primary or idiopathic PH was once considered 
a rare disease that affected young women at the 
time of the initial National Institutes of Health 
(NIH) registry [14]. Thus older patients might 
have often been not considered candidates for 
diagnosis of PH at that time. This fact has likely 
changed thus leading to an increase in the dia-
gnosis of PH especially in that subgroup (Group 
I PH). This is reinforced by the fact that the num-
ber of admissions in the age group > 85 years has 
shown a significant rise from 2000 to 2013. Thus 
increased awareness has likely played a major 
role in increasing the total number of patients 
diagnosed with PH. 
Another contributing factor is the wide spre-
ad use of doppler echocardiography and other 
imaging modalities in the community leading 
to increase in the diagnosis of PH. Papolos et al. 
recently showed that between 2001 and 2011, the 
absolute volume and incidence of echo increased 
at an average annual rate of 3.41% and 3.04% 
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respectively [15]. A  study in 2009 concluded 
that the use of computed tomography (CT) had 
doubled and the use of magnetic resonance ima-
ging (MRI) had tripled in the 10 years preceding 
the study [16]. Both these tests demonstrate an 
enlarged pulmonary arterial size or other radio-
graphical features of PH, which may lead to the 
diagnosis of PH. The rise of hospitalizations could 
also be attributed to the fact that previously dia-
gnosed PH patients might be readmitted due to an 
overall decrease in mortality as discussed later. 
Our study also demonstrated a significant, 
13% increase of length of hospital stay from 
2000 to 2013. This may seem counterintuitive 
as our diagnostic and treatment modalities have 
advanced over the analyzed time period. The 
exact reason for the increase in length of stay is 
unknown however it may be attributed to possible 
complications associated with advanced stages 
of PH disease. A German study by Wilkens et 
al. demonstrated that the average length of stay 
of PAH a patient was 11.8 ± 28.2 days [17]. As 
the availability of advanced diagnostics i.e. right 
heart catheterization become available in all 
healthcare centers the increase in the number of 
inpatient diagnostic tests could also contribute 
to the increased length of stay in these patients. 
Another recent study noted an increased frequ-
ency of cardiogenic shock, cardiac dysrhythmias, 
acute respiratory failure and renal failure in pa-
tients with PH [13], which in turn may lead to an 
increased length of stay. 
Age characteristics and payer status
There was a  trend towards admission of 
patients greater than 65 years of age that is in 
line with all recent studies that found a shift in 
diagnosis of PH to an older age [13, 18–20]. Most 
patients continued to be women in both 2000 and 
2013. There was no statistically significant incre-
ase in the frequency of men with hospitalizations 
due to PH in 2013 compared to 2000. In terms of 
payer status, we found that the highest absolute 
number of PH discharges was in the Medicare gro-
up in both 2000 and 2013. This is likely due to the 
fact that 44.4% of the patients in 2000 and 49.80% 
of the patients in 2013 were above the age of 65. 
Although there was a decrease in the number of 
PH patients with private insurance, this was likely 
a reflection of the national trend in 2013 where 
lesser patients had private insurance as compared 
to patients in 2000. The relative frequency of PH 
with private insurance actually showed a small 
increase. We noted that patients with PH were 
more likely to be admitted to private, not-for-pro-
fit hospitals. We also observed that patients with 
PH were more likely to be admitted to hospitals 
with a large number of beds as compared to ho-
spitals with a medium or small number of beds. 
This might be due to the fact that tertiary care 
hospitals, which usually have large number of 
beds, are better equipped to deal with the complex 
course of a pulmonary hypertension patient. In 
terms of regional distribution, the southern part of 
United States had the highest number of absolute 
discharges of PH patients in both 2000 and 2013. 
On the other hand, the Midwestern United States 
had the highest frequency.
Health utilization costs
We found that the aggregate hospital char-
ges adjusted for inflation for patients with PH 
increased 2.1 fold from 2000 to 2013. There are 
several possible explanations for this rise. As 
noted earlier, there is an increased frequency 
of complications in patients with PH. Increased 
complications leads to an increased length of stay 
and an associated increased cost of hospitaliza-
tion. There has also been a tremendous rise in the 
usage of diagnostic modalities amongst patients 
admitted to the hospitals in United States in the 
last decade [15, 16]. This increased use of dia-
gnostic modalities is associated with an increased 
healthcare expenditure. 
The approval of new, expensive drugs targe-
ted against WHO Group I PAH such as Epoproste-
nol, Bosentan, Sildenafil, Ambrisentan, Tadalafil 
and Riociguat have likely also contributed to the 
increased healthcare burden while the patients 
are admitted to the hospital (Fig. 4). The European 
Society of Cardiology’s practice guideline on PAH 
released in 2004 redefined PAH as per the new 
clinical classification and described an algorithm 
of various investigative tests, procedures and evi-
dence-based treatment. This likely contributed to 
an accurate diagnosis and management of PAH at 
the expense of increasing healthcare costs [21]. 
A study by Kirson et al. that analyzed a private 
insurance database from 2002–2007 demon-
strated as compared to the general population 
patients with PAH had substantially higher costs 
and comorbidity resulting in 40% of excess costs 
associated with management and treatment of 
PAH patients [22]. On the contrary, management 
of PH WHO Group II & III is focused on treatment 
of the underlying disease. Newer therapies for 
these diseases such as heart failure, chronic lung 
disease and other connective tissue disorders also 
contribute to an increased cost of hospitalization. 
This includes the use of invasive modalities and 
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implantable cardiac devices for cardiac condition 
in patients with Group II PH and the use of novel 
drugs in the treatment of patients with Group 
III PH. Our results are consistent with previous 
studies that have found an increased length of 
hospitalization and an increased inpatient cost 
for PH related hospitalizations [13]. 
As our analysis focuses on data from the 
United States, the perspective provided is that of 
a multi-payer health system that is semi privati-
zed. It is important to understand the dynamics 
of PH admission and the health utilization costs 
in single payer health systems. In a study by Vaid 
et al. [23] on Ontario in Canada, it was noted that 
there were higher hospitalization costs, nearly 
fivefold, in the cohort of PAH patients who died 
due to their disease as compared those who survi-
ved. Though this is a small sample size we are 
able to see that costs are high, and that patients 
with more severe disease have greater health 
utilization costs regardless of whether they were 
hospital or pharmaceutical related. There is yet 
to be comprehensive data on PH as a whole in 
a single payer system. From the data put forth, 
emphasis of PH should be placed on early dia-
gnosis and management. In a study by Sikirica 
[24], it was found that subjects with evidence of 
PAH had substantively high health care costs. 
Medical costs appeared to decrease following 
medication use for PAH, but with a concomitant 
increase in pharmacy costs. Cost of PH diagnosis 
and management is detrimental as there is a cor-
relation between socioeconomic status of patients 
with clinical outcomes and disease severity at 
presentation in PH [25, 26].
Mortality
Our analysis showed that there was a 23% 
reduction in mortality in 2013 as compared to 
2000 amongst patients hospitalized with diagno-
sis of PH. The mortality rate reduced from 6.69% 
in 2000 to 4.56% in 2013 (Fig. 4). The progressive 
decrease in mortality has been heralded by newer 
therapies for Group 1 and Group 4 PH and im-
provement in treatment options for chronic lung 
and chronic heart disease. An early diagnosis 
due to the increased use of imaging modalities, 
follow up at dedicated PH centers and close out-
patient follow up have all likely contributed to 
this reduced mortality. A review of the discharge 
disposition revealed that there was a significant 
increase of the number of discharges with home 
health care from 2000 to 2013. This possibly re-
flects the multiple co-morbidities as well as the 
complex nature of the patient’s illness. This also 
contributes significantly to the increased burden 
on healthcare expenditure. A significant increase 
was also seen in the number of patients dischar-
ged to a nursing home or rehabilitation facility. 
The increases in discharges to a nursing home is 
consistent with the fact that more patients admit-
ted for PH are above the age of 85 and thus are 
more likely to be nursing home residents. Patients 
with increased length of stay and associated phy-
sical debilitation are also more likely to require 
rehabilitation facilities before discharge back to 
home or nursing home. 
Limitations
The design of this study and the nature of 
the NIS database set leads to some important 
limitations. As this is an administrative data set, 
it reflects the coding practices of each institution. 
Thus it is likely that these results underestima-
te the actual number of patients admitted and 
discharged with the diagnosis of PH. It is likely 
that patient’s discharges may have been coded 
with an alternative primary diagnosis such as 
heart failure, hypoxemia, chronic lung diseases 
or other underlying connective tissue disorders 
with PH as a secondary diagnosis. For our study 
these patients were excluded as they might have 
been admitted for a non-cardiopulmonary mani-
festation and carried a secondary diagnosis of PH. 
With the use of the NIS database it would also be 
hard to calculate or determine if patients were 
admitted from the emergency room or transferred 
from community hospitals to expert PH centers. 
While it is plausible to think that hospitals were 
not able to manage these patients and thus trans-
ferred the patient to a  tertiary center, it reflects 
real world practice. In addition, this data set does 
not control for errors during the entry of the data. 
Also, patient specific clinical information was not 
obtainable which thereby limited the demographic 
data presented in the research. Results of right heart 
catheterization were not available for these patients 
and thus adherence to the diagnostic criteria for PH 
could not be confirmed. Further studies analyzing 
hospital coding practices may clarify these con-
cerns. In addition, the NIS data set does not provide 
details regarding the patient or the hospital, which 
could help us, explain the rise or decline in the 
hospital discharges and associated costs. 
Conclusion
In conclusion, PH is an escalating concern 
in the United States healthcare system. This is 
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demonstrated by the significant increase in the 
hospital cost associated with PH admissions 
from 2000 to 2013. Future studies analyzing the 
diagnostic modalities, algorithms and treatment 
practices of physician’s treating PH are necessa-
ry to reduce the burden it has on the healthcare 
system. 
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